The Opioid Epidemic in Africa and Its Impact
- 104 Downloads
Purpose of Review
Opioid use disorder (OUD) is a global phenomenon and is on the rise in Africa, denoting a shift from historical patterns of drug transport to internal consumption. In contrast, opioids for clinical pain management in Africa remain among the least available globally. This region also has the highest HIV and HCV disease burden, and the greatest shortages of health workers and addiction treatment. We undertook a systematic review of the literature to describe opioid use in Africa and how it is being addressed.
A total of 84 articles from 2000 to 2018 were identified. Descriptions of country-specific populations and patterns of opioid misuse were common. A smaller number of articles described interventions to address OUD.
OUD occurs in sub-Saharan Africa, with attendant clinical and social costs. Evidence-based policies and health system resources are needed to promote OUD prevention and management and infectious disease transmission reduction.
KeywordsAddiction Opioid use disorder Africa HIV HCV Opioid agonist treatment People who inject drugs Health workforce
We thank the colleagues engaged in opioid work and remediation in Africa.
AEK wrote the first draft, RC conducted the literature review, and all authors contributed to writing, editing, and responsibility for the final manuscript.
This project was supported in part by award number R01MH085577 from the National Institute of Mental Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health.
Compliance with Ethical Standards
Conflict of Interests
The authors declare that they have no competing interests.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 2.National AIDS Control Council (NACC). HIV prevention response and modes of transmission analysis. Nairobi, Kenya. 2009. Available at http://siteresources.worldbank.org/INTHIVAIDS/Resources/375798-1103037153392/KenyaMOT22March09Final.pdf.
- 3.UNODC. World Drug Report 2018: opioid crisis, prescription drug abuse expands; cocaine and opium hit record highs 2018. Available at https://www.unodc.org/unodc/en/press/releases/2018/June/world-drug-report-2018_-opioid-crisis%2D%2Dprescription-drug-abuse-expands-cocaine-and-opium-hit-record-highs.html. Accessed 20 September 20 2018.
- 4.• Tiberio J, Laurent YI, Ndayongeje J, Msami A, Welty S, Ngonyani A, et al. Context and characteristics of illicit drug use in coastal and interior Tanzania. Int J Drug Policy. 2018;51:20–6. https://doi.org/10.1016/j.drugpo.2017.09.012 Most studies about drug use in Tanzania are set in Dar es Salaam or Zanzibar, this is the first study that examined injection and non-injection drug use in 12 other regions in Tanzania.CrossRefPubMedGoogle Scholar
- 6.Charlson FJ, Diminic S, Lund C, Degenhardt L, Whiteford HA. Mental and substance use disorders in sub-Saharan Africa: predictions of epidemiological changes and mental health workforce requirements for the next 40 years. PLoS One. 2014;9(10):e110208. https://doi.org/10.1371/journal.pone.0110208.CrossRefPubMedPubMedCentralGoogle Scholar
- 7.WHO Statistical Information System (WHOSIS). Global Health Observatory data. Country Statistics for Tanzania and the United Kingdom. 2014. Available at http://www.who.int/gho/countries/en/.
- 9.Zumla A, Petersen E, Nyirenda T, Chakaya J. Tackling the tuberculosis epidemic in sub-Saharan Africa—unique opportunities arising from the second European developing countries clinical trials partnership (EDCTP) programme 2015-2024. Int J Infect Dis. 2015;32:46–9. https://doi.org/10.1016/j.ijid.2014.12.039.CrossRefPubMedGoogle Scholar
- 10.World Health Organization. Hepatitis C key facts, July 18, 2018. 2018. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed 14 August 2018.
- 12.UNAIDS (2018). 90-90-90: an ambitious treatment target to help end the AIDS epidemic. Available at http://www.unaids.org/en/resources/909090. Accessed 20 September 2018.
- 13.Stengel CM, Mane F, Guise A, Pouye M, Sigrist M, Rhodes T. “They accept me, because I was one of them”: formative qualitative research supporting the feasibility of peer-led outreach for people who use drugs in Dakar, Senegal. Harm Reduct J. 2018;15(1):9. https://doi.org/10.1186/s12954-018-0214-1.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.• Oyaro M, Wylie J, Chen CY, Ondondo RO, Kramvis A. Human immunodeficiency virus infection predictors and genetic diversity of hepatitis B virus and hepatitis C virus co-infections among drug users in three major Kenyan cities. South Afr J HIV Med. 2018;19(1):737. https://doi.org/10.4102/sajhivmed.v19i1.737 This paper provides prevalence of co-infection of HIV, HCV and hepatitis B virus (HBV) among people who use drugs in Nairobi, Mombasa, and Kisumu and is only one of few studies to describe the genetic diversity of HBV and HCV in this population in Kenya.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Myers B, Williams PP, Govender R, Manderscheid R, Koch JR. Substance abuse treatment engagement, completion and short-term outcomes in the Western cape province, South Africa: findings from the service quality measures initiative. Drug Alcohol Depend. 2018;185:278–84. https://doi.org/10.1016/j.drugalcdep.2017.12.033.CrossRefPubMedGoogle Scholar
- 17.• Mburu G, Ayon S, Tsai AC, Ndimbii J, Wang B, Strathdee S, et al. “Who has ever loved a drug addict? It’s a lie. They think a ‘teja’ is as bad person”: multiple stigmas faced by women who inject drugs in coastal Kenya. Harm Reduct J. 2018;15(1):29. https://doi.org/10.1186/s12954-018-0235-9 This paper provides a good overview of the challenges that females who inject drugs face including gender and power inequalities, discrimination, and being a person who uses drugs and is HIV positive.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.• Ayon S, Ndimbii J, Jeneby F, Abdulrahman T, Mlewa O, Wang B, et al. Barriers and facilitators of access to HIV, harm reduction and sexual and reproductive health services by women who inject drugs: role of community-based outreach and drop-in centers. AIDS Care. 2018;30(4):480–7. https://doi.org/10.1080/09540121.2017.1394965 This paper highlights the importance of integrating sexual and reproductive health services into community-based outreach and drop-in centers to address the unique needs of women who inject drugs.CrossRefPubMedGoogle Scholar
- 22.Semugoma NP, Rebe K, Sonderup MW, Kamkeumah M, De Swardt G, Struthers H, et al. Hepatitis C: a south African literature review and results from a burden of disease study among a cohort of drug-using men who have sex with men in Cape Town, South Africa. S Afr Med J. 2017;107(12):1116–20. https://doi.org/10.7196/SAMJ.2017.v107i12.12623.CrossRefPubMedGoogle Scholar
- 24.Parry CDH, Carney T, Petersen-Williams P. Reducing substance use and risky sexual behaviour among drug users in Durban, South Africa: assessing the impact of community-level risk-reduction interventions. Sahara J. 2017;14(1):110–7. https://doi.org/10.1080/17290376.2017.1381640.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.• Mpanza DM, Govender P. Rural realities in service provision for substance abuse: a qualitative study in uMkhanyakude district, KwaZulu-Natal, South Africa. South African Family Practice. 2017;59(3):110–5. https://doi.org/10.1080/20786190.2016.1272232 Few studies focus on the mental health service delivery in rural communities. This study examines the challenges experienced by health providers in service delivery to people who use substances in a rural setting.CrossRefGoogle Scholar
- 26.Mmbaga EJ, Moen K, Makyao N, Leshabari M. Prevalence and predictors of human immunodeficiency virus and selected sexually transmitted infections among people who inject drugs in Dar es Salaam, Tanzania: a new focus to get to zero. Sex Transm Dis. 2017;44(2):79–84. https://doi.org/10.1097/olq.0000000000000555.CrossRefPubMedGoogle Scholar
- 27.• Michie G, Hoosain S, Macharia M, Weich L. Report on the first government-funded opioid substitution programme for heroin users in the Western Cape Province, South Africa. S Afr Med J. 2017;107(6):539–42. https://doi.org/10.7196/SAMJ.2017.v107i6.12140 This study reports findings from the first publicly funded opioid agonist treatment programs in South Africa. Study findings suggest that opioid agonist treatment for OUD should be scaled up, with longer treatment durations recommended.CrossRefPubMedGoogle Scholar
- 28.Magidson JF, Gouse H, Burnhams W, Wu CY, Myers B, Joska JA, et al. Beyond methamphetamine: documenting the implementation of the matrix model of substance use treatment for opioid users in a south African setting. Addict Behav. 2017;66:132–7. https://doi.org/10.1016/j.addbeh.2016.11.014.CrossRefPubMedGoogle Scholar
- 29.• Lambdin BH, Lorvick J, Mbwambo JK, Rwegasha J, Hassan S, Lum P, et al. Prevalence and predictors of HCV among a cohort of opioid treatment patients in Dar es Salaam, Tanzania. Int J Drug Policy. 2017;45:64–9. https://doi.org/10.1016/j.drugpo.2017.05.043 This is the first study to assesses the prevalence and predictors of HCV in East Africa among PWID enrolled into opioid treatment programs (OTP). It also demonstrates that the rate of HCV was higher than expected and highlights the need to address HCV in this population.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Cooke A, Saleem H, Mushi D, Mbwambo J, Hassan S, Lambdin BH. Convenience without disclosure: a formative research study of a proposed integrated methadone and antiretroviral therapy service delivery model in Dar es Salaam, Tanzania. Addict Sci Clin Pract. 2017;12(1):23. https://doi.org/10.1186/s13722-017-0089-6.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.• Balaji D, Mlunde LB, Tran OC, Lambdin B, Mbwambo J, Nyandindi C, et al. First report of gender based violence as a deterrent to methadone access among females who use heroin in Dar es Salaam, Tanzania. AIDS Behav. 2017;21(7):2093–100. https://doi.org/10.1007/s10461-016-1529-0 This is the first study to report gender-based violence and discrimination by health care providers as barriers to accessing HIV risk reduction services for females.CrossRefPubMedGoogle Scholar
- 33.Zamudio-Haas S, Mahenge B, Saleem H, Mbwambo J, Lambdin BH. Generating trust: programmatic strategies to reach women who inject drugs with harm reduction services in Dar es Salaam, Tanzania. Int J Drug Policy. 2016;30:43–51. https://doi.org/10.1016/j.drugpo.2016.01.012.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Ubuguyu O, Tran OC, Bruce RD, Masao F, Nyandindi C, Sabuni N, et al. Improvements in health-related quality of life among methadone maintenance clients in Dar es Salaam, Tanzania. Int J Drug Policy. 2016;30:74–81. https://doi.org/10.1016/j.drugpo.2016.03.005.CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Mlunde LB, Sunguya BF, Mbwambo JK, Ubuguyu OS, Shibanuma A, Yasuoka J, et al. Correlates of health care seeking behaviour among people who inject drugs in Dar es Salaam, Tanzania. Int J Drug Policy. 2016;30:66–73. https://doi.org/10.1016/j.drugpo.2015.12.012.CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Mlunde LB, Sunguya BF, Mbwambo JK, Ubuguyu OS, Shibanuma A, Yasuoka J, et al. A mismatch between high-risk behaviors and screening of infectious diseases among people who inject drugs in Dar es Salaam, Tanzania. PLoS One. 2016;11(2):e0148598. https://doi.org/10.1371/journal.pone.0148598.CrossRefPubMedPubMedCentralGoogle Scholar
- 40.• Mital S, Miles G, McLellan-Lemal E, Muthui M, Needle R. Heroin shortage in Coastal Kenya: a rapid assessment and qualitative analysis of heroin users’ experiences. Int J Drug Policy. 2016;30:91–8. https://doi.org/10.1016/j.drugpo.2015.08.010 This study qualitatively examines the impact of the shortage of heroin on people who use heroin and adds another dimension of opioid use.CrossRefPubMedGoogle Scholar
- 42.Gouse H, Magidson JF, Burnhams W, Remmert JE, Myers B, Joska JA, et al. Implementation of cognitive-behavioral substance abuse treatment in sub-Saharan Africa: treatment engagement and abstinence at treatment exit. PLoS One. 2016;11(1):e0147900. https://doi.org/10.1371/journal.pone.0147900.CrossRefPubMedPubMedCentralGoogle Scholar
- 46.• Tun W, Sheehy M, Broz D, Okal J, Muraguri N, Raymond HF, et al. HIV and STI prevalence and injection behaviors among people who inject drugs in Nairobi: results from a 2011 bio-behavioral study using respondent-driven sampling. AIDS Behav. 2015;19(Suppl 1):S24–35. https://doi.org/10.1007/s10461-014-0936-3 This is the first study to provide population-based estimates of characteristics of PWID and HIV and sexually transmitted infection prevalence in this population in Nairobi, Kenya.CrossRefPubMedGoogle Scholar
- 47.• Tran OC, Bruce RD, Masao F, Ubuguyu O, Sabuni N, Mbwambo J, et al. Linkage to care among methadone clients living with HIV in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr. 2015;69(2):e43-e8 This study provides a descriptive overview of the first methadone treatment clinic in Tanzania, launched to address the developing HIV epidemic among PWID.CrossRefGoogle Scholar
- 49.• Syvertsen JL, Agot K, Ohaga S, Strathdee SA, Camlin CS, Omanga E, et al. Evidence of injection drug use in Kisumu, Kenya: implications for HIV prevention. Drug Alcohol Depend. 2015;151:262–6. https://doi.org/10.1016/j.drugalcdep.2015.02.037 This study provides the first descriptive analysis of injection drug use and HIV prevalence in western Kenya; this study is important because this region has the highest HIV prevalence.CrossRefPubMedPubMedCentralGoogle Scholar
- 50.Sorsdahl K, Stein DJ, Corrigall J, Cuijpers P, Smits N, Naledi T, et al. The efficacy of a blended motivational interviewing and problem solving therapy intervention to reduce substance use among patients presenting for emergency services in South Africa: a randomized controlled trial. Subst Abuse Treat Prev Policy. 2015;10:46. https://doi.org/10.1186/s13011-015-0042-1.CrossRefPubMedPubMedCentralGoogle Scholar
- 52.• Rhodes T, Guise A, Ndimbii J, Strathdee S, Ngugi E, Platt L, et al. Is the promise of methadone Kenya’s solution to managing HIV and addiction? A mixed-method mathematical modelling and qualitative study. BMJ Open. 2015;5(3):e007198. https://doi.org/10.1136/bmjopen-2014-007198 Opioid agonist treatment is promoted globally as an evidence-based intervention to treat heroin addiction among PWID and prevent HIV infection. This study mathematically models different levels of opioid agonist treatment intervention coverage, and the impact on HIV prevention in Nairobi, Kenya.CrossRefPubMedPubMedCentralGoogle Scholar
- 53.Mwatelah RS, Lwembe RM, Osman S, Ogutu BR, Aman R, Kitawi RC, et al. Co-infection burden of hepatitis C virus and human immunodeficiency virus among injecting heroin users at the Kenyan coast. PLoS One. 2015;10(7):e0132287. https://doi.org/10.1371/journal.pone.0132287.CrossRefPubMedPubMedCentralGoogle Scholar
- 54.Messersmith LJ, Adjei R, Beard J, Agyarko-Poku T, Wondergem P, Falconer A, et al. Drug use and sexual behavior: the multiple HIV vulnerabilities of men and women who inject drugs in Kumasi, Ghana. J Acquir Immune Defic Syndr. 2015;68(Suppl 2):S124–30. https://doi.org/10.1097/qai.0000000000000445.CrossRefPubMedGoogle Scholar
- 55.Meade CS, Towe SL, Watt MH, Lion RR, Myers B, Skinner D, et al. Addiction and treatment experiences among active methamphetamine users recruited from a township community in Cape Town, South Africa: a mixed-methods study. Drug Alcohol Depend. 2015;152:79–86. https://doi.org/10.1016/j.drugalcdep.2015.04.016.CrossRefPubMedPubMedCentralGoogle Scholar
- 56.Matiko E, Khatib A, Khalid F, Welty S, Said C, Ali A, et al. HIV prevalence and risk behaviors among people who inject drugs in two serial cross-sectional respondent-driven sampling surveys, Zanzibar 2007 and 2012. AIDS Behav. 2015;19(Suppl 1):S36–45. https://doi.org/10.1007/s10461-014-0929-2.CrossRefPubMedGoogle Scholar
- 57.• Lepretre A, Ba I, Lacombe K, Maynart M, Toufik A, Ndiaye O, et al. Prevalence and behavioural risks for HIV and HCV infections in a population of drug users of Dakar, Senegal: the ANRS 12243 UDSEN study. J Int AIDS Soc. 2015;18:19888. https://doi.org/10.7448/ias.18.1.19888 This study provides data on drug use, HIV and HCV and HBV infection in Senegal and is important because data from the West Africa region is often lacking.CrossRefPubMedPubMedCentralGoogle Scholar
- 58.• Kurth AE, Cleland CM, Des Jarlais DC, Musyoki H, Lizcano JA, Chhun N, et al. HIV prevalence, estimated incidence, and risk behaviors among people who inject drugs in Kenya. J Acquir Immune Defic Syndr. 2015;70(4):420–7. https://doi.org/10.1097/qai.0000000000000769 This study is one of the first to describe baseline PWID risks prior to evaluation of the potential effect of NSP in this population. In addition, this is the only study to discuss NSPs in detail.CrossRefPubMedPubMedCentralGoogle Scholar
- 61.Adebajo S, Eluwa G, Njab J, Oginni A, Ukwuije F, Ahonsi B, et al. Evaluating the effect of HIV prevention strategies on uptake of HIV counselling and testing among male most-at-risk-populations in Nigeria; a cross-sectional analysis. Sex Transm Infect. 2015;91(8):555–60. https://doi.org/10.1136/sextrans-2014-051659.CrossRefPubMedGoogle Scholar
- 63.Saban A, Flisher A, Laubscher R, London L, Morojele N. The association between psychopathology and substance use: adolescent and young adult substance users in inpatient treatment in Cape Town, South Africa. Pan Afr Med J. 2014;17(Suppl 1):8. https://doi.org/10.11694/pamj.supp.2014.17.1.3044.CrossRefPubMedPubMedCentralGoogle Scholar
- 64.Lambdin BH, Masao F, Chang O, Kaduri P, Mbwambo J, Magimba A, et al. Methadone treatment for HIV prevention-feasibility, retention, and predictors of attrition in Dar es Salaam, Tanzania: a retrospective cohort study. Clin Infect Dis. 2014;59(5):735–42. https://doi.org/10.1093/cid/ciu382.CrossRefPubMedPubMedCentralGoogle Scholar
- 67.Trenz RC, Scherer M, Duncan A, Harrell PT, Moleko AG, Latimer WW. Latent class analysis of polysubstance use, sexual risk behaviors, and infectious disease among South African drug users. Drug Alcohol Depend. 2013;132(3):441–8. https://doi.org/10.1016/j.drugalcdep.2013.03.004.CrossRefPubMedPubMedCentralGoogle Scholar
- 68.Mirzoyan L, Berendes S, Jeffery C, Thomson J, Ben Othman H, Danon L, et al. New evidence on the HIV epidemic in Libya: why countries must implement prevention programs among people who inject drugs. J Acquir Immune Defic Syndr. 2013;62(5):577–83. https://doi.org/10.1097/QAI.0b013e318284714a.CrossRefPubMedGoogle Scholar
- 69.Lambdin BH, Bruce RD, Chang O, Nyandindi C, Sabuni N, Zamudio-Haas S, et al. Identifying programmatic gaps: inequities in harm reduction service utilization among male and female drug users in Dar es Salaam, Tanzania. PLoS One. 2013;8(6):e67062. https://doi.org/10.1371/journal.pone.0067062.CrossRefPubMedPubMedCentralGoogle Scholar
- 70.Bowring AL, Luhmann N, Pont S, Debaulieu C, Derozier S, Asouab F, et al. An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011. Int J Drug Policy. 2013;24(1):78–81. https://doi.org/10.1016/j.drugpo.2012.08.005.CrossRefPubMedGoogle Scholar
- 71.Onifade PO, Somoye EB, Ogunwobi OO, Ogunwale A, Akinhanmi AO, Adamson TA. A descriptive survey of types, spread and characteristics of substance abuse treatment centers in Nigeria. Subst Abuse Treat Prev Policy. 2011;6:25. https://doi.org/10.1186/1747-597x-6-25.CrossRefPubMedPubMedCentralGoogle Scholar
- 75.Soliman CR, Rahman IA, Shawky S, Bahaa T, Elkamhawi S, El Sattar AA, et al. HIV prevalence and risk behaviors of male injection drug users in Cairo, Egypt. AIDS. 2010;24(Suppl 2):S33–8. https://doi.org/10.1097/01.aids.0000386731.94800.e6.CrossRefPubMedGoogle Scholar
- 78.Johnston LG, Holman A, Dahoma M, Miller LA, Kim E, Mussa M, et al. HIV risk and the overlap of injecting drug use and high-risk sexual behaviours among men who have sex with men in Zanzibar (Unguja), Tanzania. Int J Drug Policy. 2010;21(6):485–92. https://doi.org/10.1016/j.drugpo.2010.06.001.CrossRefPubMedGoogle Scholar
- 96.United Nations Office on Drugs and Crime (UNODC), International Centre for Health Intervention and Research in Africa (ICHIRA). Rapid situational assessment of HIV prevalence and risky behaviours among injecting drug users in Kenya. Nairobi: UNODC/ICHIRA; 2012.Google Scholar
- 97.Tanzania National AIDS Control Programme (NACP). Consensus estimates on key population size and HIV prevalence in Tanzania. Ministry of Health and Social Welfare: Dar es Salaam, Tanzania, July 2014. 2018. Available at https://www.healthpolicyproject.com/pubs/391_FORMATTEDTanzaniaKPconsensusmtgreport.pdf. Accessed on 19 August 2018.
- 99.Sullivan LE, Levine BG, Chawarski MC, Schottenfeld R, Fiellin D. Addiction and HIV in Kenya: a description of treatment services and integration. Afr J Drug Alcohol Stud. 2007;6(6):17–26.Google Scholar
- 101.World Health Organization (WHO). Expert Committee on Drug Dependence. 39th Meeting Agenda Item 5.3. 2017. Available at http://www.who.int/medicines/access/controlled-substances/PreReview_Tramadol.pdf. Accessed on 26 August 2018.
- 104.Harm Reduction International. n.d. Sub-Saharan Africa Regional Overview. Available at https://www.hri.global/sub-saharan-africa. Accessed August 26, 2018.
- 107.Ndimbii J, Guise A, Ayon S, Kalama M, McLean S, Rhodes T. Implementing needle and syringe programmes in Kenya: changes, opportunities and challenges in HIV prevention. Afr J Drug Alcohol Stud. 2015;14(2):95–103.Google Scholar
- 108.WHO, UNODC, UNAIDS. WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users—2012 revision. 2013. Available at http://www.who.int/hiv/pub/idu/targets_universal_access/en/. Accessed 19 August 2018.
- 109.WHO. Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users. 2004. Available at http://www.who.int/hiv/pub/prev_care/effectivenesssterileneedle.pdf. Accessed 19cAugust 2018.
- 110.UNAIDS, WHO (2007). Guide to starting and managing needle and syringe programmes. Available at http://www.who.int/hiv/idu/OMSEA_NSP_Guide_100807.pdf. Accessed 19 August 2018.
- 111.CDC (2018). Syringe Service Programs. Available at https://www.cdc.gov/hiv/risk/ssps.html. Accessed on 19 August 2018.
- 115.McNeil Jr. DG. ‘Opiophobia’ has left Africa in Agony. 2017. Retrieved from https://www.nytimes.com/2017/12/04/health/opioids-africa-pain.html.